Cargando…

Probiotic Engineering and Targeted Sonoimmuno‐Therapy Augmented by STING Agonist

Tumor targeting and effective immunomodulation are of critical significance during tumor treatment by sonodynamic therapy (SDT). Herein, the probiotic engineering of the clinically approved sonosensitizer (hematoporphyrin monomethyl ether (HMME)) is reported onto the probiotic bacterium Bifidobacter...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Dan, Wang, Liying, Wang, Liping, An, Liwei, Huo, Minfeng, Xu, Huixiong, Shi, Jianlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353485/
https://www.ncbi.nlm.nih.gov/pubmed/35603970
http://dx.doi.org/10.1002/advs.202201711
_version_ 1784762873851936768
author Lu, Dan
Wang, Liying
Wang, Liping
An, Liwei
Huo, Minfeng
Xu, Huixiong
Shi, Jianlin
author_facet Lu, Dan
Wang, Liying
Wang, Liping
An, Liwei
Huo, Minfeng
Xu, Huixiong
Shi, Jianlin
author_sort Lu, Dan
collection PubMed
description Tumor targeting and effective immunomodulation are of critical significance during tumor treatment by sonodynamic therapy (SDT). Herein, the probiotic engineering of the clinically approved sonosensitizer (hematoporphyrin monomethyl ether (HMME)) is reported onto the probiotic bacterium Bifidobacteria Longum (BiL) for sonosensitive bifidobacterium construction (HMME@BiL cells). Based on the hypoxic tropism feature of the strain, effective tumor‐targeted sonodynamic therapeutics can be achieved both in vitro and in vivo. To improve the immunological responses against tumor during sonodynamics, a recently‐developed stimulator of interferon genes immune agonist SR717 has been employed to improve the anti‐tumor immunity with prominent activities, eradicating both primary and metastatic tumors with high efficiency and satisfied biocompatibility. The present work provides a promising paradigm of microbiotic nanomedicine in a sophisticated sonoimmunotherapeutic strategy against malignant tumors.
format Online
Article
Text
id pubmed-9353485
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93534852022-08-09 Probiotic Engineering and Targeted Sonoimmuno‐Therapy Augmented by STING Agonist Lu, Dan Wang, Liying Wang, Liping An, Liwei Huo, Minfeng Xu, Huixiong Shi, Jianlin Adv Sci (Weinh) Research Articles Tumor targeting and effective immunomodulation are of critical significance during tumor treatment by sonodynamic therapy (SDT). Herein, the probiotic engineering of the clinically approved sonosensitizer (hematoporphyrin monomethyl ether (HMME)) is reported onto the probiotic bacterium Bifidobacteria Longum (BiL) for sonosensitive bifidobacterium construction (HMME@BiL cells). Based on the hypoxic tropism feature of the strain, effective tumor‐targeted sonodynamic therapeutics can be achieved both in vitro and in vivo. To improve the immunological responses against tumor during sonodynamics, a recently‐developed stimulator of interferon genes immune agonist SR717 has been employed to improve the anti‐tumor immunity with prominent activities, eradicating both primary and metastatic tumors with high efficiency and satisfied biocompatibility. The present work provides a promising paradigm of microbiotic nanomedicine in a sophisticated sonoimmunotherapeutic strategy against malignant tumors. John Wiley and Sons Inc. 2022-05-23 /pmc/articles/PMC9353485/ /pubmed/35603970 http://dx.doi.org/10.1002/advs.202201711 Text en © 2022 The Authors. Advanced Science published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Lu, Dan
Wang, Liying
Wang, Liping
An, Liwei
Huo, Minfeng
Xu, Huixiong
Shi, Jianlin
Probiotic Engineering and Targeted Sonoimmuno‐Therapy Augmented by STING Agonist
title Probiotic Engineering and Targeted Sonoimmuno‐Therapy Augmented by STING Agonist
title_full Probiotic Engineering and Targeted Sonoimmuno‐Therapy Augmented by STING Agonist
title_fullStr Probiotic Engineering and Targeted Sonoimmuno‐Therapy Augmented by STING Agonist
title_full_unstemmed Probiotic Engineering and Targeted Sonoimmuno‐Therapy Augmented by STING Agonist
title_short Probiotic Engineering and Targeted Sonoimmuno‐Therapy Augmented by STING Agonist
title_sort probiotic engineering and targeted sonoimmuno‐therapy augmented by sting agonist
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353485/
https://www.ncbi.nlm.nih.gov/pubmed/35603970
http://dx.doi.org/10.1002/advs.202201711
work_keys_str_mv AT ludan probioticengineeringandtargetedsonoimmunotherapyaugmentedbystingagonist
AT wangliying probioticengineeringandtargetedsonoimmunotherapyaugmentedbystingagonist
AT wangliping probioticengineeringandtargetedsonoimmunotherapyaugmentedbystingagonist
AT anliwei probioticengineeringandtargetedsonoimmunotherapyaugmentedbystingagonist
AT huominfeng probioticengineeringandtargetedsonoimmunotherapyaugmentedbystingagonist
AT xuhuixiong probioticengineeringandtargetedsonoimmunotherapyaugmentedbystingagonist
AT shijianlin probioticengineeringandtargetedsonoimmunotherapyaugmentedbystingagonist